CClinicalTrials.gg
CompletedNCT05536453Updated Oct 20, 2025

Retro Comparison of Subsidence Following Interbody Devices in Lumbar Spine

An observational study in Degenerative Disc Disease (DDD), sponsored by Spine and Scoliosis Research Associates. Completed at 4 sites in United States. Open to participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2025-10-20.

Sponsored by Spine and Scoliosis Research Associates · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
465
Ages
18 Years to 110 Years
Sex
All
01

Study summary

The objective of this retrospective study is an investigational clinical follow-up, of patients treated with interbody fusion devices (IBFD), both expandable (EXP) and static (STC), according to their intended use and cleared labeling to understand IBFD design and technique characteristics that affect occurrence rates of subsidence.

Patients treated with IBFD's (both EXP and STC) according to their intended use and cleared labeling

  1. EXP IBFD's that expand in width and height demonstrate reduced occurrence of subsidence post-operatively when compared to EXP IBFD's that expand in height only and STC IBFD's.
  2. EXP IBFD's that are comprised of multi-material composition with Polyetheretherketone (PEEK) endplate contacting surfaces demonstrate reduced occurrence of subsidence on post-operative radiographs when compared to EXP and STC IBFD's that are primarily comprised of Ti with Ti endplate contacting surfaces.
  3. achieve radiographic fusion at a rate consistent with the state-of-the-art
  4. achieve significant improvements in pain and function compared to baseline
  5. experience adverse events at a frequency comparable to reported rates for TLIF or PLIF surgery
  6. not demonstrate any intraoperative complications during the implant process
  7. operative approach does not correlate with increased rates of subsidence
02

Conditions studied

  • Degenerative Disc Disease (DDD)
03

In context

Intervertebral Disc Degeneration

464 studies on the registry are indexed under Intervertebral Disc Degeneration; 98 are open to participants now.

This study's enrollment of 465 is above the median of 120 across 166 observational studies indexed under Intervertebral Disc Degeneration.

Browse Intervertebral Disc Degeneration studies →

Lead sponsor

Spine and Scoliosis Research Associates is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 110 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Skeletally mature individuals with degenerative disc disease (DDD) of the lumbar spine at one or two contiguous levels from L2 to S1, who were treated with TLIF or PLIF surgery using an EXP or STC IBFD according to the surgeon's and patient's choice, as part of the standard of care.

Inclusion criteria

1. The patient was treated with TLIF or PLIF surgery using the IBFD according to the cleared labeling, based on the surgeon's clinical judgment and patient-specific decision making. Based on the product labeling, the patient must:

  1. Was at least 18 years of age and skeletally mature at the time of surgery
  2. Had clinical and radiological evidence of DDD of the lumbar spine
  3. Undergone treatment with the IBFD with autogenous bone graft and/or allogeneic bone graft composed of cancellous and/or corticocancellous bone at 1 or 2 contiguous levels from L2 to S1

Exclusion criteria

Exclusion Criteria:

  1. History of fusion surgery or large laminectomy at L2 to S1 prior to treatment with the IBFD(s) Spondylolisthesis unable to be reduced to grade 1 as part of the surgical procedure
  2. Surgery with the IBFD(s) at more than 2 contiguous levels
  3. Surgery with the IBFD(s) at levels outside the range of L2 to S1
  4. Treated with any bone grafting material other than autogenous or allogenic bone graft in the device(s) or surrounding disc space
  5. Any contraindications listed in the cleared product labeling
  6. Osteoporosis, Other Systemic Bone D.O. T score ≤ -1.5
  7. BMI > 40
  8. Systemic Infection
  9. H/O IV Drug Use
  10. Cancer
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
465 participants (actual)
Patient registry
No

Interventions

  • DeviceLumbar Interbody Fusion Devices

    Posterior Lumbar Interbody Fusion device placed to treat symptoms associated with degenerative disc disease

    Also known as: Static Posterior Lumbar Interbody Fusion (PLIF) cages, Expandable PLIF cages, Static Transforaminal Lumbar Interbody Fusion (TLIF) cages, Expandable TLIF cages

06

What researchers measure

Primary outcomes

  1. Incidence of Subsidence

    Radiographic subsidence immediately postoperatively (first erect), at 12 months, and at 24 months as evaluated by an independent reviewer. Where subsidence is defined as ≥ 2mm cage penetration of the cephalad, caudal end plate, or both. Intraoperative subsidence will be classified when fluoroscopic images identify end plate violation, and postoperative subsidence is classified by the absence of violation on intraoperative fluoroscopy, but present on 12-month lateral radiographs and/or 24 months.

    Time frame: 24 months

Secondary outcomes

  1. Incidence of Fusion

    Radiographic fusion at 12 months and at 24 months follow-up, as evaluated by up to 3 independent reviewers (2 primary reviewers and 1 adjudicator, as needed for disagreements). Fusion status will be determined according to the Bridwell-Lenke grading system (Bridwell et al. 1995), with grades 1-2 accepted as "Fused" and grades 3-4 accepted as "Not Fused." For subjects determined to be fused at 12 months, additional X-rays will not be required at 24 months unless the treating surgeon determines that radiographs are otherwise needed for the patient. The last-observation-carried-forward (LOCF) approach will be employed for 24-month fusion assessments where additional radiographs were not collected beyond 12 months.

    Time frame: 24 months

  2. Incidence of End Plate Violation

    Incidence of end plate violation determined based upon operative reports and medical records.

    Time frame: 12 months

  3. Visual Analog Scale (VAS) Scores for Leg Pain, if available

    Comparison of VAS scores for leg pain between baseline and 12 months post-operatively and baseline and 24 months post-operatively. The scores range from 0 to 100, with higher numbers indicating more pain.

    Time frame: 24 months

  4. VAS Scores for Back Pain, if available

    Comparison of VAS scores for back pain between baseline and 12 months post-operatively and baseline and 24 months post-operatively. The scores range from 0 to 100, with higher numbers indicating more pain.

    Time frame: 24 months

  5. Oswestry Disability Index (ODI) Scores, if available

    Comparison of ODI scores between baseline and 12 months post-operatively and baseline and 24 months post-operatively. The scores range from 0 to 100, with higher numbers indicating more disability.

    Time frame: 24 months

  6. Incidence of Device and/or Procedure-Related Adverse Events

    Incidence of device and/or procedure-related adverse events determined based upon operative reports and medical records.

    Time frame: 24 months

07

Study locations

4 sites
  • University of California San Francisco
    San Francisco, California 94143, United States
  • New York University Langone Health
    New York, New York 10016, United States
  • Carolina NeuroSurgery & Spine Associates
    Charlotte, North Carolina 28204, United States
  • Rothman Orthopaedic Institute
    Bensalem, Pennsylvania 19020, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05536453
Lead sponsor
Spine and Scoliosis Research Associates
Responsible party
Sponsor
First posted
Sep 10, 2022
Start date
Aug 16, 2022
Primary completion
Jul 16, 2025
Completion
Jul 16, 2025
Last update
Oct 20, 2025

Study contacts

Aaron Buckland, MD
principal investigator · SSRA Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion